ALBENDAZOLE | A208094 | ACTAVIS ELIZABETH LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Amedra Pharmaceuticals LLC - Citizen Petition FDA-2013-P-0766 · 5 docket documents Amedra Pharmaceuticals LLC filed this citizen petition on June 18, 2013, requesting that the FDA refrain from approving any abbreviated new drug application for a generic version of ALBENZA (albendazole) tablets unless the applicant demonstrates bioequivalence based on systemic levels of the primary | 505(q) | 2013-07-16 | Denied | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$4.36
per ea
Lowest NADAC/Unit
$4.36
per ea
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00591271202ALBENDAZOLE 200 MG TABLET | $4.36 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.